open access

Vol 28, No 4 (2022)
Research paper
Published online: 2022-12-30
Get Citation

Comparison between unfractionated heparin (UFH) and fondaparinux on platelets and D-dimer level in COVID-19 patients with hypercoagulation

Meity Ardiana1, Hanestya Oky Hermawan1, Primasitha Maharany Harsoyo1, Inna Maya Sufiyah1, Mohammad Fahrizal Fanani1
DOI: 10.5603/AA.2022.0015
·
Acta Angiologica 2022;28(4):161-165.
Affiliations
  1. Airlangga University, Indonesia

open access

Vol 28, No 4 (2022)
Original papers
Published online: 2022-12-30

Abstract

Introduction: This study aimed to compare the clinical effects between UFH and fondaparinux
in COVID-19 patients with hypercoagulation.

Material and methods: This was a prospective cohort study. Samples were taken consecutively from hospitalized
COVID-19 patients with hypercoagulation who received UFH or fondaparinux based on the standardized
guidelines. A total of 71 patients met the inclusion criteria. Patients were evaluated for platelet and D-dimer
values before and after administration of UFH or fondaparinux.

Results: Although there was no difference in D-dimer reduction between the two groups (p = 0.44), fondaparinux
showed a greater reduction, 26% against 22% for UFH. While on platelets, there was a significant
difference (p = 0.04) between fondaparinux and UFH. Fondaparinux showed a reduced thrombocytopenia
impact, as seen by an increase in pre- and post-therapy platelets of up to 50%, compared to 16% in UFH.
In regard to the incidence of Heparin-Induced Thrombocytopenia (HIT), there was no significant difference
between post-UFH therapy and post-fondaparinux therapy (p = 0.361).

Conclusion: Fondaparinux did not reduce platelet levels as much as UFH, but there was no difference
between the fondaparinux group compared to the UFH group in the effect of decreasing D-dimer levels and
the sign of HIT.

Abstract

Introduction: This study aimed to compare the clinical effects between UFH and fondaparinux
in COVID-19 patients with hypercoagulation.

Material and methods: This was a prospective cohort study. Samples were taken consecutively from hospitalized
COVID-19 patients with hypercoagulation who received UFH or fondaparinux based on the standardized
guidelines. A total of 71 patients met the inclusion criteria. Patients were evaluated for platelet and D-dimer
values before and after administration of UFH or fondaparinux.

Results: Although there was no difference in D-dimer reduction between the two groups (p = 0.44), fondaparinux
showed a greater reduction, 26% against 22% for UFH. While on platelets, there was a significant
difference (p = 0.04) between fondaparinux and UFH. Fondaparinux showed a reduced thrombocytopenia
impact, as seen by an increase in pre- and post-therapy platelets of up to 50%, compared to 16% in UFH.
In regard to the incidence of Heparin-Induced Thrombocytopenia (HIT), there was no significant difference
between post-UFH therapy and post-fondaparinux therapy (p = 0.361).

Conclusion: Fondaparinux did not reduce platelet levels as much as UFH, but there was no difference
between the fondaparinux group compared to the UFH group in the effect of decreasing D-dimer levels and
the sign of HIT.

Get Citation

Keywords

COVID-19; hypercoagulation; unfractionated heparin (UFH); fondaparinux; heparin-induced thrombocytopenia (HIT)

About this article
Title

Comparison between unfractionated heparin (UFH) and fondaparinux on platelets and D-dimer level in COVID-19 patients with hypercoagulation

Journal

Acta Angiologica

Issue

Vol 28, No 4 (2022)

Article type

Research paper

Pages

161-165

Published online

2022-12-30

Page views

508

Article views/downloads

65

DOI

10.5603/AA.2022.0015

Bibliographic record

Acta Angiologica 2022;28(4):161-165.

Keywords

COVID-19
hypercoagulation
unfractionated heparin (UFH)
fondaparinux
heparin-induced thrombocytopenia (HIT)

Authors

Meity Ardiana
Hanestya Oky Hermawan
Primasitha Maharany Harsoyo
Inna Maya Sufiyah
Mohammad Fahrizal Fanani

References (20)
  1. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
  2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–1242.
  3. Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29: 100639.
  4. Tiwari NR, Khatib KI, Dixit SB, et al. Anticoagulation in COVID - 19: An Update. J Crit Care Med (Targu Mures). 2020; 6(4): 217–223.
  5. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017; 129(21): 2864–2872.
  6. Kumar P, Mediwake R, Rhead C. A matter of time: duration and choice of venous thromboprophylaxis in patients diagnosed with COVID-19. Br J Hosp Med (Lond). 2020; 81(5): 1–2.
  7. Iba T, Levy JH, Levi M, et al. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020; 48(9): 1358–1364.
  8. Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223): 514–523.
  9. Xu P, Zhou Qi, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020; 99(6): 1205–1208.
  10. Güçlü E, Kocayiğit H, Okan HD, et al. Effect of COVID-19 on platelet count and its indices. Rev Assoc Med Bras (1992). 2020; 66(8): 1122–1127.
  11. Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology. 2021; 88(1): 15–27.
  12. Alban S. Adverse Effects of Heparin. Heparin - A Century of Progress. 2011: 211–263.
  13. Warkentin TE. Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia: Too Good to Be True? J Am Coll Cardiol. 2017; 70(21): 2649–2651.
  14. Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent). 2012; 25(1): 13–15.
  15. Chong BH, Chong JJH. Heparin-induced thrombocytopenia associated with fondaparinux. Clin Adv Hematol Oncol. 2010; 8(1): 63–65.
  16. Marongiu F, Barcellona D. Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? TH Open. 2020; 4(4): e300–e302.
  17. Linkins LA. Heparin induced thrombocytopenia. BMJ. 2015; 350: g7566.
  18. Negri EM, Piloto BM, Morinaga LK, et al. Heparin Therapy Improving Hypoxia in COVID-19 Patients - A Case Series. Front Physiol. 2020; 11: 573044.
  19. Lazaridis D, Leung S, Kohler L, et al. The Impact of Anticoagulation on COVID-19 (SARS CoV-2) Patient Outcomes: A Systematic Review. J Pharm Pract. 2022; 35(6): 1000–1006.
  20. Sholzberg M, Tang GH, Rahhal H, et al. RAPID Trial investigators. Heparin for Moderately Ill Patients with Covid-19. medRxiv. 2021.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl